TSE:HBP Helix BioPharma (HBP) Stock Price, News & Analysis C$1.58 0.00 (0.00%) As of 06/5/2026 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsBuy This Stock About Helix BioPharma Stock (TSE:HBP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Helix BioPharma alerts:Sign Up Key Stats Today's RangeC$1.55▼C$1.5850-Day RangeC$1.51▼C$2.0552-Week RangeC$0.84▼C$5.40Volume1,500 shsAverage Volume2,634 shsMarket CapitalizationC$120.68 millionP/E RatioN/ADividend Yield1.50%Price TargetN/AConsensus RatingN/A Company Overview Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today's hardest-to-treat cancers. The Company's pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today's front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix's next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery. The Company also advances two pre-IND candidates: (i) LEUMUNA¿, an oral immune checkpoint modulator aimed at achieving durable remission in post-transplant leukemia relapse, and (ii) GEMCEDA¿, a first-in-class oral gemcitabine prodrug with bioavailability on a par with IV, designed to expand treatment options for advanced cancers. Read More Receive HBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Helix BioPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HBP Stock News HeadlinesHelix BioPharma Showcases CEACAM6-Targeted ADC Advances at World ADC LondonFebruary 24, 2026 | tipranks.comHelix BioPharma Extends LEUMUNA Option with metaShape in Metabolic Disease PushFebruary 5, 2026 | tipranks.com$36 million a day says something big is comingInstitutional capital is flowing into one thesis at a rate of $36 million per day - $25,000 every single minute. Morgan Stanley puts the addressable market at $5 trillion, and the smart money is already positioned. Pentagon-funded research from Rensselaer Polytechnic Institute identified a precise tipping point: once roughly 10% of a population adopts a new idea, the rest of the system flips fast. That threshold was just crossed. Porter Stansberry, with nearly 30 years in the markets, says this opportunity is bigger than dot-com, crypto, and the 2023 AI rally combined.June 8 at 1:00 AM | Porter & Company (Ad)Helix BioPharma Shareholders Back Board, Auditor and Share Consolidation PlanJanuary 30, 2026 | tipranks.comHelix BioPharma Reports Fiscal 2025 Results and Strategic DevelopmentsOctober 29, 2025 | tipranks.comHelix BioPharma Addresses Unusual Market Activity Amidst Ongoing Cancer Treatment DevelopmentsOctober 6, 2025 | tipranks.comHelix BioPharma to Present at Q3 2025 Investor Summit and Plans NASDAQ UplistingSeptember 9, 2025 | tipranks.comHelix BioPharma Corp.: Helix BioPharma Announces Presentation at Q3 Investor Summit Virtual on 16 September 2025September 9, 2025 | finanznachrichten.deSee More Headlines HBP Stock Analysis - Frequently Asked Questions How have HBP shares performed this year? Helix BioPharma's stock was trading at C$2.37 at the start of the year. Since then, HBP shares have decreased by 33.3% and is now trading at C$1.58. How were Helix BioPharma's earnings last quarter? Helix BioPharma Corp. (TSE:HBP) issued its quarterly earnings results on Monday, March, 16th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter. How do I buy shares of Helix BioPharma? Shares of HBP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Helix BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Helix BioPharma investors own include Enterprise Products Partners (EPD), GrowGeneration (GRWG), Green Thumb Industries (GTBIF), Amplify Seymour Cannabis ETF (CNBS), Cenovus Energy (CVE), Enbridge (ENB) and Micron Technology (MU). Company Calendar Last Earnings3/16/2026Today6/08/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:HBP CIKN/A Webwww.helixbiopharma.com Phone+1-416-9253232FaxN/AEmployees9Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$50.55 million Net MarginsN/A Pretax MarginN/A Return on Equity-36.79% Return on Assets-279.98% Debt Debt-to-Equity Ratio2.34 Current Ratio0.04 Quick Ratio1.04 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.14 per share Price / Cash Flow11.32 Book ValueC$0.20 per share Price / Book7.86Miscellaneous Outstanding Shares76,378,000Free FloatN/AMarket CapC$120.68 million OptionableNot Optionable Beta0.42 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (TSE:HBP) was last updated on 6/8/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm NOT Buying the SpaceX IPO (And What I'm Buying Instead)The media's calling it "the biggest IPO in Wall Street history." But I'm not buying it. Institutions got into ...Decentralized Masters | SponsoredThe "hidden" half of the SpaceX IPOMost investors are focused on the SpaceX IPO - but the bigger opportunity may lie elsewhere. On Feb. 2, Elon M...Weiss Ratings | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredStranded On The Flood Plains of HistoryThe petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed...Porter & Company | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour name isn't on our protected list yetI checked our download records for "The Big Beautiful Bubble Report" and didn't see your name. That concern...American Alternative | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredSpaceX billions need somewhere to go — this is itThe SpaceX IPO is projected to raise $75 billion in a single day... When that happens, the insiders who cashed...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Helix BioPharma Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Helix BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
